Potential Cost-Effectiveness of Pneumococcal Conjugate Vaccine (PCV) in Turkey

ABSTRACT Background Pneumococcal infection is an important and preventable cause of morbidity and mortality. The Turkish government introduced 7-valent pneumococcal conjugate vaccine (PCV) into the national immunization program in 2009. This suggests that replacing 7-valent PCV with a higher-valent...

Full description

Saved in:
Bibliographic Details
Published in:Value in health 2013-07, Vol.16 (5), p.755-759
Main Authors: Türel, Özden, MD, Kisa, Adnan, MSPH, PhD, McIntosh, E. David G., MBBS, MPH, LLM, PhD, Bakir, Mustafa, MD
Format: Article
Language:English
Subjects:
Biological and medical sciences
burden of disease
children
Cost effectiveness
Cost-Benefit Analysis
General aspects
Humans
Immunization
Immunization Programs - economics
Internal Medicine
Medical sciences
Miscellaneous
Morbidity-Mortality
Paediatrics
Planification. Prevention (methods). Intervention. Evaluation
Pneumococcal Infections - economics
Pneumococcal Infections - prevention & control
Pneumococcal Vaccines - administration & dosage
Pneumococcal Vaccines - economics
pneumonia
Public health. Hygiene
Public health. Hygiene-occupational medicine
Streptococcus pneumoniae
Turkey
Vaccines
Vaccines, Conjugate - administration & dosage
Vaccines, Conjugate - economics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Background Pneumococcal infection is an important and preventable cause of morbidity and mortality. The Turkish government introduced 7-valent pneumococcal conjugate vaccine (PCV) into the national immunization program in 2009. This suggests that replacing 7-valent PCV with a higher-valent version could at least maintain “standard of care” if not improve it, and that it could be affordable. Objectives and Methods The aim of this analysis was to assess the potential direct cost-effectiveness of 13-valent PCV in Turkey, a country with a birth cohort of 1.4 million, against a “no vaccine” state, against the default 7-valent PCV state, and against a 10-valent PCV state, using a published cohort model with a 5-year horizon. Results and Conclusions The cost per life-year gained is below the 1 × per-capita gross domestic product threshold across large changes in key input parameters, indicating that the model is stable and suggesting that any PCV would be very cost-effective in a Turkish national pediatric immunization schedule.
ISSN:1098-3015
1524-4733
DOI:10.1016/j.jval.2013.03.1632